Table 2.
Overview of studies in pretreatment cystatin C levels and survival prognosis in patients with urogenital malignancy.
| Number | Author | Type | Year | Cases | Stage | Treatment | Kind of sampling | Cut-off value | Cases of high-CysC group (%) | Multivariate Cox analysis | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Guo et al. | RCC | 2017 | 325 | All stage | Nephrectomy | Serum | 1.09 | 109 (34) | OS HR:1.59 (1.10-2.29), P= 0.012 PFS HR:3.50 (1.29-9.51), P=0.013 | (49) |
| 2 | Zhao et al. | RCC | 2020 | 354 | All stage | Nephrectomy | Serum | 1.105 | 36 (10) | OS HR:10.513 (2.539-43.522), P=0.001 CSS HR:4.944 (1.017-24.043), P=0.048 | (41) |
| 3 | Bodnar et al. | RCC | 2016 | 56 | Metastatic | MMT (Everolimus) | Serum | 1.15 | 44 (79) | OS HR:2.60 (1.03-2.60), P= 0.0428 PFS HR:2.85 (1.34-6.05), P=0.0065 | (39) |
| 4 | Guo et al. | clear cell RCC | 2018 | 253 | All stage | Nephrectomy | tissues | 29.65 | 210 (83) | OS HR:5.98 (0.8-44.33), P=0.079 | (42) |
| 5 | Fan et al. | PC | 2017 | 54 | CRPC | Chemotherapy (Docetaxel+Prednisone) | Serum | 1.61 | 23 (43) | OS HR:2.394 (1.135-3.757), P= 0.001 | (46) |
| 6 | Tan et al. | UTUC | 2019 | 538 | No distant metastasis | RNU | Serum | 1.4 | 162 (30) | OS HR:1.989 (1.366-2.896), P<0.001 RFS HR:1.429 (1.009-2.023), P=0.044 CSS HR:1.997 (1.331-2.996), P=0.001 | (67) |
RCC, renal cell carcinoma; PC, prostate cancer; UTUC, upper tract urothelial carcinoma; CRPC, castration-resistant prostate cancer; MMT, molecular-targeted therapy; RNU, radical nephroureterectomy; OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; RFS, progression-free survival, HR, hazard ratio; CI, confidence interval.